STVN Share Price Performance
US$21.76
-0.71 (-3.16%)
5.4% undervalued intrinsic discount
US$23.00
Fair Value
Price US$21.76
AnalystLowTarget US$23.00
AnalystHighTarget US$37.00
AnalystConsensusTarget US$28.78
Fair ValueUS$23.00
Share Pricen/a
Stevanato Group S.p.A. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
STVN Community Narratives
AN
Fair Value US$23 5.4% undervalued intrinsic discount
Rising Regulatory Costs And Local Rivalry Will Compress Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$36.07 39.7% undervalued intrinsic discount
Automation And Biologics Adoption Will Transform Injectable Solutions
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$28.78 24.4% undervalued intrinsic discount
US Onshoring And Rising Biologics Demand Will Reshape Drug Delivery
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
US Onshoring And Rising Biologics Demand Will Reshape Drug Delivery
Key Takeaways Expanding demand for advanced drug delivery and containment solutions, driven by trends in biologics, self-administration, and pharmaceutical industry investments, is boosting Stevanato's revenue and growth prospects. Investments in manufacturing capacity and innovation, alongside regulatory-driven market dynamics, are supporting higher margins, pricing power, and improved earnings quality.Read more
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$28.78
24.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
9.38% p.a.
Profit Margin
16.69%
Future PE
36.26x
Price in 2028
US$39.09
Rising Regulatory Costs And Local Rivalry Will Compress Margins
Key Takeaways Heightened regulatory and market shifts threaten Stevanato's product relevance, margins, and demand, forcing potential redesigns and eroding pricing power. Rising local competition and evolving drug delivery technologies risk undercutting global expansion efforts and diminishing returns from recent investments.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$23
5.4% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
8.26% p.a.
Profit Margin
16.71%
Future PE
29.31x
Price in 2028
US$30.47
Automation And Biologics Adoption Will Transform Injectable Solutions
Key Takeaways Rapid growth in high-value biologics and innovative delivery formats positions Stevanato for accelerated earnings and above-expectation margin expansion as premium products ramp. Vertical integration, strong regulatory credibility, and alignment with pharma industry supply trends create durable competitive advantages and long-term profitable client relationships.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$36.07
39.7% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
10.27% p.a.
Profit Margin
16.87%
Future PE
43.13x
Price in 2028
US$47.91
Trending Discussion
Recently Updated Narratives
AN
STVN: German Facility Expansion Will Drive Stronger Supply Chain Integration
Fair Value: US$28.78 24.4% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Regulatory Costs And Local Rivalry Will Compress Margins
Fair Value: US$23 5.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Automation And Biologics Adoption Will Transform Injectable Solutions
Fair Value: US$36.07 39.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Stevanato Group S.p.A. Key Details
About STVN
- Founded
- 1949
- Employees
- 5521
- CEO
- WebsiteView website
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug product, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
